| Bioactivity | Trimethobenzamide (Ro 2-9578 free base) is a blocker of the D2 receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting[1]. |
| Target | D2 receptor |
| Invitro | Trimethobenzamide is a (non-phenothiazine) benzamide antiemetic that acts centrally to block D2 receptors, thereby inhibiting the medullary chemoreceptor trigger zone by blocking emetic impulses to the vomiting center[1]. |
| In Vivo | The oral bioavailability of Trimethobenzamide is 60% to 100%. The time to peak is about 45 minutes after oral administration and; Intramuscular (I.M.) administration about 30 minutes after intramuscular administration[1]. |
| Name | Trimethobenzamide |
| CAS | 138-56-7 |
| Formula | C21H28N2O5 |
| Molar Mass | 388.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Smith HS, et al. Dopamine receptor antagonists. Ann Palliat Med. 2012 Jul;1(2):137-42. |